Analysis of The BCG Vaccine Market Size | USD 12.2 Bn & CAGR 7.55% Growth By 2035

BCG Vaccine Market Size and Forecast

According to analysts at Vantage Market Research, the global BCG (Bacillus Calmette-Guerin) Vaccine Market is projected to witness significant growth in the coming years, with a market value of USD 5.5 billion in 2024, expected to reach USD 12.2 billion by 2035. This represents a compound annual growth rate (CAGR) of 7.55% from 2025 to 2035. The growth of the market can be attributed to several factors, including the increasing prevalence of tuberculosis (TB), advancements in vaccine research and development, and the rise in government-led vaccination campaigns aimed at combating the spread of TB. Tuberculosis, despite being preventable and treatable, continues to be a major global health concern. According to the World Health Organization (WHO), tuberculosis was ranked as the 13th leading cause of death worldwide in 2021, with an estimated 10.6 million new cases and 1.6 million deaths.

Key Highlights of BCG Vaccine Market

• In 2023, the Asia Pacific region dominated the market, representing over 60.5% of the overall revenue share
• North America will likely exhibit the fastest growth rate during the forecast time
• The Pediatrics (0-18 Years) segment took the lead in the market in 2023, holding a significant revenue share of 75.2%
• The Retail Pharmacy segment significantly contributed to the market’s expansion, constituting over 50.3% of the overall revenue share in 2023
• According to ACVIP, India accounted for 26% of TB cases worldwide. TB of the brain, i.e., the most dangerous form of childhood TB, has the maximum rate in children <5 years of age
• In July 2023, UNICEF issued a Request for Proposals (RFP) for the supply of BCG Vaccine from 2024 to 2035
• BCG Vaccine is a quite affordable vaccine with a current 2023 estimated Weighted Average Price (WAP) of USD 0.14 per dose

Download Sample Report PDF (Including Full TOC, Table & Figures) @ https://www.vantagemarketresearch.com/bcg-vaccine-market-2427/request-sample

The BCG vaccine, which is primarily used to prevent TB, has been a critical tool in the fight against the disease, especially in high-prevalence countries. In addition to preventing tuberculosis, the BCG vaccine is effective in preventing certain forms of TB, such as military tuberculosis and tuberculous meningitis in children, which are particularly devastating in regions with high TB rates. Given the vaccine’s role in reducing the incidence of these severe forms of TB, millions of people globally have received the BCG vaccination. This widespread use has contributed significantly to the prevention of TB in many countries, particularly in regions where the disease remains endemic.

However, despite the benefits, the BCG vaccine is not without its limitations. The vaccine's efficacy in preventing adult pulmonary tuberculosis, the most common form of TB, remains inconsistent. Additionally, the BCG vaccine can interfere with the results of tuberculin skin tests used to diagnose latent TB infections, further complicating its use in certain populations. As a result, in some developed nations like the United States, where TB is less prevalent, the BCG vaccine is not routinely recommended for general use. This has led to a slower vaccine adoption in such regions, potentially limiting the market's growth in these countries.

On the other hand, in low- and middle-income countries where the burden of tuberculosis is significantly higher, the demand for the BCG vaccine is expected to increase. Factors such as poverty, homelessness, and the high prevalence of HIV are known to contribute to the higher incidence of TB in these regions. The BCG vaccine remains the only effective vaccine available to protect against mycobacterium tuberculosis, the bacteria responsible for TB. In many of these countries, the healthcare infrastructure is often under-resourced, making vaccination campaigns crucial in reducing the spread of the disease. Additionally, healthcare professionals working in high-incidence areas of tuberculosis in these regions are at an increased risk of contracting latent tuberculosis infection (LTBI). A recent study published in the European Respiratory Journal highlighted the alarming rate at which healthcare workers in these regions test positive for TB-related infections. In the study, 50% of healthcare professionals and nearly 32% of healthcare students tested positive for tuberculin skin disease. In comparison, 25% and 39% of the same groups tested positive for interferon-gamma release assay (IGRA), a test to detect latent and active TB infections. This high rate of TB exposure among healthcare workers underscores the need for continued vaccination efforts, as they are at an elevated risk of TB transmission.

The growing incidence of tuberculosis in these regions and the ongoing challenges of healthcare access and infrastructure are expected to drive the demand for the BCG vaccine in the coming years. As governments and international organizations prioritize TB control programs and vaccination campaigns, the global market for BCG vaccines is poised to grow. Technological advancements in vaccine development and improvements in delivery mechanisms are also likely to contribute to the expansion of the market. Furthermore, the ongoing global efforts to eliminate tuberculosis as a public health threat are expected to fuel the demand for BCG vaccines further, especially in high-risk populations and regions with limited healthcare access.

While challenges remain regarding the BCG vaccine's inconsistent efficacy and limited use in certain developed countries, the increasing prevalence of tuberculosis in low—and middle-income nations, coupled with growing awareness and government initiatives, is expected to drive the market for BCG vaccines forward. With continued research and development efforts, the BCG vaccine market will likely see sustained growth, contributing to the global fight against tuberculosis and other mycobacterial infections.

Market Dynamics

The global Bacille Calmette-Guérin (BCG) vaccine market is significantly influenced by the rising prevalence of tuberculosis (TB), technological advancements in vaccine research and development, and the growing support from government initiatives to expand vaccination programs. These market dynamics collectively contribute to the demand for BCG vaccines and are pivotal to combating the ongoing TB crisis, particularly in regions with a high disease burden.

Take Action Now: Secure Your Position in the Global BCG Vaccine Industry Today – Purchase Now.

Rising Prevalence of Tuberculosis

One of the primary drivers of the BCG vaccine market is the increasing global incidence of tuberculosis. According to the World Health Organization’s Global Tuberculosis Report 2022, TB cases worldwide surged to 10.6 million in 2021, a 3.6% increase from the previous year. This upward trend is alarming, especially as TB remains one of the leading causes of death worldwide. The rising incidence rate highlights the urgent need for effective preventive measures, and the BCG vaccine continues to play a crucial role in this regard. Particularly concerning is the rise in drug-resistant TB, including rifampicin-resistant strains, which presents a more significant challenge for treatment and underscores the importance of preventing the spread of the disease through vaccination.

The impact of tuberculosis on children is especially distressing. Data from UNICEF in June 2022 revealed that approximately 7.5 million children aged 0-14 years are infected with latent tuberculosis annually, with 1-1.2 million progressing to active TB disease. The vulnerability of children, especially those under the age of five, to severe forms of TB like meningitis highlights the critical need for the BCG vaccine in pediatric populations. The BCG vaccine has demonstrated its effectiveness, offering up to 80% protection against severe childhood TB, including TB meningitis. This makes it an essential tool in preventing the spread of TB among the most vulnerable populations, thus driving the demand for the vaccine.

Technological Advancements in Vaccine Research and Development

Technological innovation in vaccine development is another key factor propelling the BCG vaccine market. The field of vaccine research has evolved significantly, incorporating advanced technologies such as DNA-subunit vaccines, RNA-lipoplexes, nanoparticles, and viral vector systems. These advancements enhance the safety and efficacy of vaccines, including BCG, which is traditionally used to prevent TB.

One such innovation is the development of recombinant BCG vaccines, which involve genetic modifications to enhance the vaccine’s protective properties. For example, the Serum Institute of India has been working on a recombinant BCG vaccine that integrates foreign genes or overexpresses native genes into the BCG bacterium. This development represents a significant leap forward in vaccine technology, potentially improving the BCG vaccine’s effectiveness and broadening its application beyond TB prevention. In January 2023, the National Institute of Tuberculosis Research in Chennai initiated clinical trials for a new BCG vaccine, demonstrating ongoing efforts in advancing vaccine research. These technological advancements are expected to boost the BCG vaccine market further, offering more effective solutions to combat tuberculosis.

Rise in Government Initiatives for Vaccination Programs

Government support and initiatives are instrumental in driving the BCG vaccine market. Public health strategies to increase immunization coverage and ensure that vaccines reach high-risk populations are critical components in the global effort to control tuberculosis. For example, in March 2022, Thailand expanded its immunization program to include the BCG vaccine for all children, reflecting the government’s commitment to increasing vaccination rates. A robust government-backed immunization program in Saudi Arabia resulted in a 94.1% coverage rate for BCG vaccinations in 2021. These national efforts demonstrate governments' crucial role in ensuring widespread vaccination, thus driving demand for BCG vaccines.

Additionally, international initiatives further support the market. For instance, in October 2022, the Government of Japan contributed USD 1.5 million to UNICEF to help Uganda track under-immunized and unimmunized children for various vaccinations, including BCG. Similarly, healthcare institutions, such as the Birmingham Community Healthcare NHS Foundation Trust in the UK, have implemented phased introductions of BCG immunization programs, ensuring that high-risk populations are vaccinated against TB. These coordinated efforts by governments and healthcare organizations are essential for maintaining high vaccination rates, particularly in regions where TB remains endemic.

The expanding role of governments in funding and promoting vaccination campaigns ensures that the BCG vaccine remains a critical tool in the global fight against tuberculosis. Such efforts help mitigate the spread of TB, reduce morbidity and mortality rates, and ultimately drive the demand for BCG vaccines, particularly in low- and middle-income countries where the disease burden is highest.

In conclusion, the BCG vaccine market is experiencing significant growth due to the rising prevalence of tuberculosis, advancements in vaccine technology, and increasing support from governments worldwide. These factors collectively drive the demand for the BCG vaccine, ensuring it remains vital in the global effort to control and prevent tuberculosis, especially in regions with a high disease burden. With continued innovation in vaccine development and sustained government initiatives, the market for BCG vaccines is poised for sustained growth in the years ahead.

View the full report now for the BCG Vaccine Market Research Report and updates!

COVID-19 Scenario Insights

The outbreak of the COVID-19 pandemic, which began in late December 2019 in Wuhan, China, has had significant global health and economic implications. However, the pandemic has not negatively affected the BCG (Bacillus Calmette-Guérin) vaccine market. The pandemic has had a somewhat positive impact on the market. Despite the widespread disruptions caused by COVID-19, BCG vaccination rates among pediatric populations have remained steady, particularly in countries where TB is prevalent. This is largely due to the continued recognition of BCG’s critical role in preventing severe tuberculosis in children.

Furthermore, early in the pandemic, there was growing interest in exploring the potential protective effects of the BCG vaccine against COVID-19. Some countries conducted clinical trials to assess whether the BCG vaccine could reduce susceptibility to SARS-CoV-2 or alleviate the severity of the disease. Although the results of these trials were mixed, the exploration of BCG as a potential COVID-19 preventative measure brought additional attention to the vaccine and its benefits. As a result, the BCG vaccine market saw a boost in interest and demand, particularly in the context of global public health efforts to combat COVID-19.

The market for BCG vaccines is segmented based on demographics, focusing on pediatric populations (0-18 years) and adults (19-35 years). Additionally, the market is analyzed regionally across Asia-Pacific, LAMEA (Latin America, Middle East, Africa), and the Rest of the World, with demand varying according to regional TB prevalence and healthcare infrastructure.

The BCG (Bacillus Calmette-Guérin) vaccine market is seeing notable segmentation trends across different age groups, distribution channels, and regions, each contributing to the industry's overall growth. The segment breakdown offers valuable insights into where the demand for BCG vaccines is strongest, how it is distributed, and which regions are leading the vaccine adoption.

Segment Insights

By Age Group

• Pediatrics (0-18 Years)
• Adults (19-35 Years)

In 2023, the Pediatrics segment (0-18 years) was the dominant driver of the BCG vaccine market, representing a substantial 75.2% of total revenue. The global emphasis on vaccinating infants and young children against tuberculosis has led to the overwhelming dominance of this age group in the market. BCG vaccination is particularly critical in childhood because young children are at a higher risk of developing severe forms of tuberculosis, such as TB meningitis, compared to adults. The BCG vaccine provides protection of up to 80% against these serious childhood TB complications, making it an essential component of national immunization programs in countries with a high TB burden.

Global statistics on childhood tuberculosis further underscore the importance of pediatric vaccination. According to the India TB Report 2022 published by the Ministry of Health & Family Welfare Government of India, childhood tuberculosis accounts for about 31% of the global TB burden. This highlights the significant challenge that pediatric TB poses and the role of BCG vaccination in addressing it. In regions with high TB prevalence, the BCG vaccine is often administered to newborns and young children to prevent the spread of the disease. This underscores why the Pediatrics segment holds a commanding market share, as childhood tuberculosis remains a persistent challenge requiring proactive prevention efforts.

By Distribution Channel Overview

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

The Distribution Channel segment within the global BCG vaccine market has seen significant growth, particularly within the Retail Pharmacy category, which accounted for 50.3% of the market revenue in 2023. The expansion of the retail pharmacy segment can be attributed to several factors, including increasing awareness about the importance of tuberculosis prevention, the growing demand for immunization services, and improved healthcare access in various regions.

Retail pharmacies have become a key point of contact for individuals seeking vaccinations, particularly in countries where healthcare infrastructure may not be as robust or access to hospitals may be limited. The convenience and accessibility of retail pharmacies have made them increasingly pivotal in distributing and administering BCG vaccines. This has led to an increase in the adoption of the vaccine, particularly in regions where the availability of immunization services is expanding. Retail pharmacies are also supported by governments and health organizations' broader efforts to increase vaccination coverage and reduce TB incidence. The ease of obtaining vaccinations from retail pharmacies contributes to the overall accessibility of TB prevention measures, which has fueled the demand for BCG vaccines in this distribution channel.

By Regional Insights

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Regarding regional adoption, North America—particularly the United States—has been a key player in the global BCG vaccine market. However, it faces relatively lower TB incidence rates compared to other regions. The United States follows a stringent regulatory framework for the use of the BCG vaccine, which is primarily recommended for individuals at high risk of exposure to drug-resistant tuberculosis or those who cannot be treated with standard TB medications. The Centers for Disease Control and Prevention (CDC) provides clear guidelines on BCG vaccination, ensuring its use among high-risk populations. Although the incidence of TB is lower in North America, the region remains focused on maintaining strong TB prevention strategies, which has increased awareness of the vaccine's importance.

In 2021, the BCG vaccine coverage rate in the U.S. was reported to be around 75%, reflecting the region's commitment to childhood immunization programs as part of a broader effort to control tuberculosis. The high level of healthcare accessibility in North America, coupled with well-established medical infrastructure, further supports the efficient distribution of the BCG vaccine. This includes advanced cold chain logistics, well-trained healthcare professionals, and comprehensive reimbursement policies, which collectively ensure the effective administration of the vaccine. Additionally, North America is home to leading pharmaceutical companies such as Merck & Co., Sanofi, and the Serum Institute of India, contributing to the regional supply and research of BCG vaccines. These companies' strong distribution networks and research capabilities help meet the demand for the vaccine and position North America as a critical market for BCG vaccine producers.

Several factors across different segments are driving the BCG vaccine market. The Pediatrics segment remains the dominant contributor, as childhood vaccination against tuberculosis remains a priority in many high-TB-burden countries. The growing role of retail pharmacies in the distribution channel highlights the increasing accessibility and convenience of obtaining the vaccine, contributing to higher vaccination rates. Regionally, North America remains a strong player in the market, with its robust healthcare infrastructure and focused regulatory policies supporting the adoption of the BCG vaccine. These trends are expected to continue driving market growth as global efforts to combat tuberculosis remain a public health priority, particularly for vulnerable populations like children.

The BCG Vaccine market is characterized by a competitive landscape with several key players actively working to enhance vaccine accessibility, improve efficacy, and broaden distribution networks. Companies in the market continually invest in research and development (R&D) efforts to improve the existing BCG vaccine or explore new avenues for tuberculosis prevention. This competitive dynamic is fueled by the ongoing global efforts to combat tuberculosis, a disease that continues to have a significant public health impact, particularly in developing countries.

Competitive Landscape

One of the most notable players in the BCG Vaccine market is the Serum Institute of India, based in Pune. As one of the world’s largest vaccine manufacturers, the Serum Institute is critical in addressing global immunization needs. It is a significant supplier of BCG vaccines worldwide, contributing substantially to tuberculosis prevention. The company’s ability to produce vaccines on a large scale has made it an essential partner in global TB eradication efforts. The Serum Institute has also shown a strong commitment to innovation, continuously exploring new ways to improve the efficacy and administration of the BCG vaccine. Its efforts in R&D are designed to overcome challenges such as inconsistent efficacy against adult pulmonary TB and the vaccine’s interference with tuberculin skin tests.

Other key players in the BCG Vaccine market include Merck & Co. Inc., AJ Vaccines A/S, Japan BCG Laboratory, Green Signal Bio Pharma Private Limited, and the Torlak Institute of Virology. These companies develop, produce, and distribute BCG vaccines globally. They also work on improving the vaccine’s effectiveness and addressing any limitations in its current use. Competition among these players is intense, as each company strives to enhance its market share while contributing to global efforts to prevent tuberculosis.

A recent market development highlighting the competitive landscape occurred in January 2024 when Serum Institute of India joined an expanding network of vaccine producers supported by the Coalition for Epidemic Preparedness Innovations (CEPI). This partnership reflects Serum Institute’s ongoing efforts to play a pivotal role in ensuring equitable access to vaccines during public health outbreaks, further solidifying its standing in the global vaccine market. By joining this network, Serum Institute is reinforcing its position as a major contributor to public health responses, particularly in regions most vulnerable to diseases like tuberculosis. This move is expected to enhance the company's global reach and accelerate its vaccine development and distribution efforts, especially in low- and middle-income countries where tuberculosis remains a major health concern.

Top 6 Key players in the BCG Vaccine Industry

• Serum Institute of India Pvt. Ltd.
• Merck & Co. Inc.
• AJ Vaccines A/S
• Japan BCG Laboratory
• Green Signal Bio Pharma Private Limited
• Torlak Institute of Virology

Geography BCG Vaccine Market in Healthcare Industry Insights

The global BCG (Bacillus Calmette-Guérin) vaccine market is experiencing substantial growth driven by diverse geographical factors influencing the healthcare landscape, public health policies, and market demand. The BCG vaccine market's geography segment analysis reveals growth patterns, challenges, and opportunities in key regions such as North America, Europe, Asia-Pacific, and the Rest of the World. These regions are at different stages of vaccine adoption and healthcare development, with governments, pharmaceutical companies, and healthcare institutions playing vital roles in shaping the market dynamics.

Market in North America: In North America, the BCG vaccine market benefits from a well-established healthcare infrastructure, robust regulatory frameworks, and strong research and development activities. The United States, Canada, and Mexico collectively drive the market's growth, with particular emphasis on the rising prevalence of bladder cancer and tuberculosis cases and advancements in vaccine technology.

Market in the United States: The United States holds the largest share of the North American BCG vaccine market, accounting for approximately 66% of the regional market. Its advanced healthcare infrastructure, high research and development investments, and comprehensive vaccination programs underpin the U.S. market's dominance. The prevalence of bladder cancer in the country also contributes to the strong demand for the BCG vaccine, as it is used as an immunotherapy for the treatment of superficial bladder cancer. Additionally, the increasing awareness of tuberculosis prevention and the support from healthcare reimbursement policies bolster market growth in the U.S. Key players in the industry and ongoing clinical trials further strengthen the market's position in the region.

Market in Mexico: Mexico is emerging as the fastest-growing market in North America, with a projected growth rate of approximately 4% from 2024 to 2029. The country’s market growth is primarily driven by government initiatives to enhance tuberculosis prevention and control programs. Efforts to improve healthcare access in underserved areas, coupled with rising awareness of tuberculosis and vaccine availability, contribute to the expanding market in Mexico. As the healthcare system continues to strengthen, the demand for vaccines, including BCG, is expected to rise, supporting the country’s growing market trajectory.

Market in Europe: Europe has a sophisticated healthcare infrastructure, with countries like Germany, the United Kingdom, France, Italy, and Spain leading the BCG vaccine market. The region benefits from well-established immunization programs, strong governmental support, and a coordinated approach to tuberculosis control. Europe's research institutions and pharmaceutical companies contribute significantly to vaccine development and market expansion.

Market in Italy: Italy holds a significant share of the European BCG vaccine market, commanding approximately 22% of the regional market. The country’s strategic approach to tuberculosis prevention and comprehensive national immunization program support its market leadership. Italy’s healthcare system emphasizes preventive care, especially for pediatric populations, and continues to prioritize tuberculosis prevention. Public awareness campaigns, government health initiatives, and effective vaccination programs contribute to Italy’s sustained position as a key player in the European market.

Market in Germany: Germany is projected to be the fastest-growing market in Europe, with an expected growth rate of around 6% from 2024 to 2029. The country’s focus on technological advancements in vaccine research and development is a key driver of market expansion. With substantial healthcare investments and a well-established public health framework, Germany is increasingly investing in tuberculosis prevention measures: government initiatives to promote vaccination programs and growing public awareness about tuberculosis fuel market growth in the region.

Market in Asia-Pacific: The Asia-Pacific region is home to a large and diverse population with significant potential for growth in the BCG vaccine market. Countries like China, India, Japan, Australia, and South Korea are at varying stages of vaccine adoption, with governments and healthcare organizations focusing on improving immunization programs and healthcare infrastructure. Rising healthcare expenditures and increased awareness about tuberculosis prevention are key factors contributing to market growth in the region.

Market in China: China dominates the Asia-Pacific BCG vaccine market due to its vast population and extensive vaccination programs. The country’s robust pharmaceutical manufacturing capabilities and government support for vaccine production further solidify its position in the regional market. China’s comprehensive national immunization program and significant investments in healthcare infrastructure ensure wide vaccine coverage, driving the demand for BCG vaccines. Additionally, the government’s ongoing research and development efforts support continued market expansion.

Market Growth in China: China is also emerging as the fastest-growing market in the Asia-Pacific region, with rapid growth attributed to government investments in healthcare infrastructure and vaccine development. The country’s focus on advancing vaccine production technologies, along with efforts to improve healthcare accessibility, supports the expanding demand for BCG vaccines. Furthermore, growing public awareness about tuberculosis prevention and control measures helps drive market development in China.

Market in the Rest of the World: The Rest of the World region, which includes a diverse mix of emerging markets across Africa, the Middle East, and Latin America, also demonstrates considerable potential for the growth of the BCG vaccine market. Government initiatives to improve vaccination coverage and strengthen healthcare systems are crucial regional drivers. International health organizations' support for vaccination programs further contributes to market expansion, particularly in areas with high tuberculosis prevalence.

Countries in this region focus on improving healthcare accessibility and implementing comprehensive immunization programs to combat tuberculosis. As tuberculosis remains a major public health concern, efforts to increase awareness and provide equitable access to vaccines will continue to drive the BCG vaccine market in the Rest of the World.

The global BCG vaccine market is characterized by diverse geographical dynamics, with different regions exhibiting varying levels of market development, growth potential, and healthcare infrastructure. While North America and Europe lead in healthcare infrastructure and advanced research, the Asia-Pacific and Rest of the World offer significant growth opportunities due to their large populations and increasing focus on tuberculosis prevention. Governments and healthcare organizations across these regions play a crucial role in supporting vaccination programs, driving market expansion, and ensuring the widespread availability of the BCG vaccine.

FAQ.

1. What is the projected growth rate of the global BCG vaccine market between 2025 and 2035?
2. How does the increasing prevalence of tuberculosis contribute to the demand for the BCG vaccine?
3. What technological advancements influence the BCG vaccine's development and effectiveness?
4. How are government initiatives and vaccination programs driving the growth of the BCG vaccine market?
5. What role does the pediatric population (0-18 years) play in the overall BCG vaccine market?
6. How does the BCG vaccine’s use in bladder cancer immunotherapy impact the market?
7. What challenges do companies face in expanding the BCG vaccine market in low- and middle-income countries?
8. How do regional differences in tuberculosis prevalence affect the demand for BCG vaccines?
9. How has the COVID-19 pandemic impacted the global BCG vaccine market?
10. Who are the key players in the BCG vaccine market, and what recent developments have they made in vaccine production?

Browse More Health Care Industry News

• According to analysts at Vantage Market Research, the global BCG Vaccine Market is projected to witness significant growth in the coming years. With a market value of USD 5.5 billion in 2024, it is expected to reach USD 12.2 billion by 2035. This represents a compound annual growth rate (CAGR) of 7.55% from 2025 to 2035.
• The global Vaccines Market was valued at USD 87.57 billion in 2024 and is projected to reach USD 206.78 billion by 2035, at a CAGR (Compound Annual Growth Rate) of 8.15% between 2025 and 2035.
• The global Therapeutic Vaccines Market was valued at USD 59.35 billion in 2024 and is projected to reach USD 181.79 billion by 2035, at a CAGR (Compound Annual Growth Rate) of 10.75% between 2025 and 2035.
• The global Peptide Cancer Vaccine Market is projected to reach a value of USD 5.9 billion by 2032 at a CAGR (Compound Annual Growth Rate) of 48.0% between 2024 and 2032.